Navigation Links
Hyperion Therapeutics Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of GT4P in Patients With Urea Cycle Disorders
Date:10/23/2007

of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. The most common adverse reactions are vomiting (9%), hypokalemia (7%), hyperglycemia (7%), convulsions (6%), and mental impairments (6%). Do not administer to patients with known hypersensitivity to sodium phenylacetate or sodium benzoate. Acute symptomatic hyperammonemia should be treated as life-threatening. Uncontrolled hyperammonemia can result in brain damage or death. Dialysis may be required, preferably hemodialysis, to remove a large burden of ammonia. Administration must be through a central line; use of a peripheral line may cause burns. Do not administer undiluted product. Because of prolonged plasma levels achieved by phenylacetate in pharmacokinetic studies, repeat loading doses should not be administered. Use caution when administering to patients with hepatic or renal insufficiency. AMMONUL(R) may cause nausea and vomiting. An antiemetic may be administered during infusion. See the prescribing information for a complete listing of warnings, precautions, and drug interactions.

About BUPHENYL(R)

BUPHENYL(R) is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). BUPHENYL(R) should not be administered to patients with known hypersensitivity to sodium phenylbutyrate or any component of this preparation. The most common adverse reactions associated with BUPHENYL(R) were amenorrhea dysfunction, decreased appetite, body odor (probably caused by its metabolite phenylacetate) and bad taste or taste aversion. Patients with urea cycle disorders should not take valproic acid, haloperidol, or steroids as these drugs have been reported to increase blood ammonia levels, and probenecid may affect the kidneys' excretion. Use with great care, if at all, in patients wi
'/>"/>

SOURCE Hyperion Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015  Perrigo Company plc ("Perrigo") (NYSE: ... the acquisition of leading OTC brands from GSK in ... transaction is a clear demonstration of Perrigo,s unique ability ... distribution network spanning 36 countries.  Perrigo ... commented, "We are excited to complete this transaction, which ...
(Date:8/28/2015)... Massachusetts y LONDRES, 28 de agosto ... AEX: PHIA) anunció hoy su participación en el  ... exhibirá sus soluciones cardiológicas más recientes y novedosas, ... Cardiovascular, que conectan a las personas y la ... de ayudar a diagnosticar, guiar los tratamientos y ...
(Date:8/27/2015)... DURECT Corporation (Nasdaq: DRRX ) announced ... upcoming healthcare conferences.  , James ... the Rodman & Renshaw Investment Conference on Thursday, September ... being held at the St. Regis Hotel in ... webcast of the presentation will be available by accessing ...
Breaking Medicine Technology:Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5DURECT to Participate in Upcoming Healthcare Conferences 2
... , ALLEGAN, Mich., Nov. 19 Perrigo Company ... and CEO Joseph C. Papa will present at the Sidoti ... (EST) at the Grand Hyatt Hotel in New York City. ... supplier that develops, manufactures and distributes OTC and prescription pharmaceuticals, ...
... Nov. 19 Delcath Systems, Inc. (Nasdaq: DCTH ), ... (PHP(TM)) System, a minimally invasive drug delivery platform for the ... on the Company,s recent progress. , "Since we last communicated ... many significant milestones as we move into the first regulatory ...
Cached Medicine Technology:Delcath Systems Reports Substantial Progress 2Delcath Systems Reports Substantial Progress 3Delcath Systems Reports Substantial Progress 4
(Date:8/30/2015)... ... August 30, 2015 , ... SonaCare Medical, ... the treatment of prostate cancer, has announced the roll-out of its newest technology ... center in Puerto Vallarta, Mexico. , The Sonablate® technology currently in use at ...
(Date:8/29/2015)... ... 30, 2015 , ... On September 30, 2015, the Career and Transfer Center ... accredited Maricopa Community Colleges , will be hosting a Job Expo to provide ... and opportunities. , The Expo has expanded to much more than just a typical ...
(Date:8/29/2015)... ... , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the Director of Policy ... present an educational program titled “Asbestos and Your Health.” , The two and one ... at 6:45pm) at Calvary United Methodist Church, 16 E Park Ave., Ambler, PA 19002. ...
(Date:8/29/2015)... ... August 29, 2015 , ... It can be ... against dribbled urine and sweat. "In order to prevent these problems, I conceived ... ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support for a male’s crotch. It ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... Dr. Tim ... mission. His mission is to increase acceptance of the chiropractic field in the ... that further debilitate them. Although Chiropractic was made available to the VA program ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2
... supplements containing the mycoestrogen zearalenone (ZEN), a naturally occurring ... their risk of breast cancer. That is the warning ... ahead of print publication in the January issue of ... Practice . "No clinical trials have been published ...
... Australia, cancer incidence rates have increased while deaths from cancer ... a recent study published early online in the Asia-Pacific ... disease group, cancer has the greatest overall impact on Australians, ... in five dying from it before the age of 85. ...
... early-stage HER2-positive breast cancer may have worse ... Mayo Clinic researchers found in a study presented today ... Symposium . HER2-positive breast cancer gets its name from ... that promotes cancer cell growth. "Not only did ...
... the results of a new study published in the ... African-Americans, Hispanics and uninsured patients use fewer post-hospitalization services ... care, and rehabilitation. Notably, the authors found ... a few categories, while disparities were highest among the ...
... HealthDay Reporter , WEDNESDAY, Dec. 7 (HealthDay News) -- Multiple ... and work its way into the deep interior, according to ... system disease. The new findings, which could spur changes ... solidify a theory that,s emerged in recent years. This new ...
... in children or adults, often takes place even in ... obesity. Current methods to treat such overeating in ... eat, requiring them to track their food intake and ... such behavioral therapy techniques don,t work long term, according ...
Cached Medicine News:Health News:Women advised to avoid ZEN bust-enhancing supplements because of possible cancer risk 2Health News:Study sheds light on cancer burden in Australia 2Health News:Mayo Clinic: Obese patients with HER2-positive breast cancer may have worse outcomes 2Health News:Racial, ethnic and insurance disparities revealed in post-hospital care after trauma 2Health News:Racial, ethnic and insurance disparities revealed in post-hospital care after trauma 3Health News:MS May Take a Different Pathway Than Previously Thought 2Health News:MS May Take a Different Pathway Than Previously Thought 3Health News:New approach to management of overeating in children 2Health News:New approach to management of overeating in children 3
... Now there is a more efficient ... first fully portable battery operated patient ... and surgical teams with a compact ... throughout the entire surgical process. Its ...
... CSZ safely provides effective air warming therapy ... patented design of our WarmAir® FilteredFlo® blankets, ... which supplies gently moving, clean air that ... contaminants to your patient or staff. All ...
Since 1964, in its plants of Sesto Fiorentino, Sbisà produces a wide and qualified range of instruments for ophthalmology and optometry....
Inquire...
Medicine Products: